Cancer-related fatigue (CRF) is subjective and has wide inter-individual variability.
| INTRODUC TI ON
The estimated incidence of cancer-related fatigue (CRF) has been reported to range from 28% to 91% among breast cancer patients, 1 depending on the type of cancer, treatment modality and method of assessment. CRF is characterised by a persistent sense of tiredness that may be related to cancer and/or cancer treatment, is disproportionate to recent activity and is not alleviated by rest. 2 Left unresolved, CRF adds on to patients' distress and has a negative impact on their quality of life. 3 Given the extent of the impact of CRF on daily functioning, 4 addressing CRF should be an integral part of cancer-supportive care. Nevertheless, this has proved challenging due to the lack of an objective biomarker to monitor these symptoms. The experience of fatigue is subjective in nature and has wide inter-individual variability because some patients may have poor physical functioning and impaired performance status yet will not complain of fatigue, and vice versa. One study has shown that pro-inflammatory cytokines could be potentially employed as biomarkers of CRF in patients with advanced cancer, 5 and that changes from baseline of selected biomarkers were associated with changes in patient-reported outcome measures of appetite and fatigue.
However, the circadian variability and fluctuation of cytokine levels could influence the outcomes associated with the biomarkers used and hinder their utility. 6 Thus, further research is warranted to determine a suitable biomarker for monitoring CRF and related symptoms in cancer patients.
Leptin is an endocrine hormone that is more commonly known for its metabolic effects, which range from appetite suppression to regulating body weight. 7 Leptin has shown moderate correlations to varying extents with fatigue in cohorts of patients with cardiovascular risk factors (r = 0.22), 8 chronic fatigue syndrome (r = −0.51 to 0.73), 6 chronic hepatitis C infection (r = 0.25; r = 0.30), 9, 10 and irritable bowel syndrome (r = 0.60). 11 In another study, researchers found that plasma leptin levels could be induced by hydrocortisone, and were markedly increased in patients with chronic fatigue syndrome. 12 Hence, we hypothesized that leptin levels may be positively correlated with increases in fatigue in cancer patients, as their pro-inflammatory markers are typically elevated.
This study was designed to investigate the association between plasma leptin levels and CRF in a cohort of early-stage breast cancer patients, in relation with other relevant clinical factors and adipokines. Our primary objective was to assess leptin's potential to function as a biomarker that could predict the onset of CRF.
| MATERIAL S AND ME THODS

| Study design
This prospective cohort study was conducted between 2014 and 2017 in Singapore. The study was approved by the Singhealth Institutional Review Board (CIRB 2014/754/B), and written informed consent was obtained from all study participants. 
| Inclusion and exclusion criteria
| Study procedures
Patients were assessed at three time points: baseline before treatment initiation (T1), at least 6 weeks after baseline during chemotherapy (T2), and at least 12 weeks after baseline after the completion of chemotherapy (T3). Upon recruitment, patients' demographic information and medication information were collected through patient interviews and electronic databases. The longitudinal association of CRF with plasma leptin and adipokine levels was assessed using the generalised estimating equation model. The correlation structure with the smallest criterion was chosen using the quasi-likelihood under the independence model criterion. Leptin was first analysed as a single variable. Next, the following known confounders that affect CRF were analysed individually against total MFSI-score across the time points: anxiety, 25 depression, 25 
| Study tools
| RE SULTS
| Patient demographics
A total of 136 early-stage breast cancer patients were included in this analysis, and their demographics are summarised in 
| Prevalence of cancer-related fatigue
Using the MCID as a cut-off, patients who experienced a deterioration of ≥11 points from baseline were considered as fatigue cases. A total of 23.8% of patients experienced CRF at T3 compared to 13.8% of patients at T2, using the baseline as a reference. The overall incidence of CRF from T1 to T3 was 24.6%.
| Plasma levels of adipokines and leptin across time points
The plasma levels of the individual adipokines are summarised as the medians with the interquartile ranges ( Table 2 ). There were statistically significant changes in the plasma levels of leptin, IL-6, Il-8
and TNF-α across the three time points (P-value <0.001 using the Friedman test). Compared to baseline, a median increase of plasma leptin levels was observed at T2, followed by a decrease at T3 (T1:
4.07 ng/mL, T2: 4.95 ng/mL and T3: 3.96 ng/mL). For IL-6, there was an increase in plasma levels towards the end of chemotherapy at T3 (T1: 0.80 pg/mL, T2: 1.11 pg/mL, T3: 1.27 pg/mL). For IL-8, there was a decrease in plasma levels at T2, followed by an increase at T3 (T1: 3.70 pg/mL, T2: 3.33 pg/mL, T3: 3.69 pg/mL). For TNF-α, there was a sustained increase in plasma levels (T1: 6.41 pg/mL, T2:
6.95 pg/mL, T3: 8.27 pg/mL).
| Correlation of plasma adipokines levels and confounders against plasma leptin levels at individual time points
Considering relationships between leptin and each individual adipokine, only IL-8 had a statistically significant correlation at T1
(r = 0.20, P = 0.02). At T1, there were no significant correlations between leptin and IL-6 or TNF-α. At T2 and T3, none of the adipokines showed statistically significant correlations with leptin (Table 3) . there was a difference in plasma leptin levels for menopausal status at T1 and T3 (P = 0.002 and 0.01 respectively), for anaemia status at T2
(P = 0.02) and the type of chemotherapy at T2 (P = 0.03).
| Correlation of plasma adipokines levels, known confounders and leptin against fatigue levels across time points (T1-T3)
There were consistent strong correlations with fatigue levels across all time points for anxiety, depression and insomnia. Age was negatively correlated with CRF across time points and CRF level also differed for the type of chemotherapy. There was only a significant negative correlation at T1 for leptin (r = −0.25, P = 0.005) ( Table 4) .
Across T1 to T3, leptin was negatively correlated with the total MFSI-SF score (β = −0.56, P < 0.001), with every 1 unit decrease of leptin being associated with a 0.56 increase in total MFSI-SF score ( Table 2) and BMI (β = −0.39, P = 0.13) were not significantly correlated with total MFSI-SF score.
| Adjusted model showing an association between leptin and CRF
Using P-values <0.05 as selection criteria, the variables with statistically significant associations with CRF were TNF-α, anxiety, unit decrease of leptin being associated with a 0.14 increase in total MFSI-SF score across time points (Table 5) .
While leptin was originally associated with the general (β = −0.16, P < 0.001), emotional (β = −0.11, P < 0.001) and mental sub-domains (β = −0.06, P = 0.025) of MFSI-SF scale, the beta coefficients of the respective five sub-domains scores were not statistically significant in the final model (Table 6 ). In the analysis of other explanatory variables in the final model, there were positive significant associations with CRF for anxiety (β = 0.74, P < 0.001) and depression (β = 1.06, P < 0.001) and significant negative associations for TNF-α (β = −0.009, P < 0.001) and age (β = −0.23, P = 0.004).
| D ISCUSS I ON
In our cohort of early-stage breast cancer patients, plasma leptin levels were found to be significantly and negatively correlated with total MFSI-SF score across time points (β = −0.56, P < 0.01). This relationship remained significant (β = −0.15, P = 0.003) even after adjusting for the statistically significant covariates in our final model.
This result does not support our initial hypothesis, in which we predicted that leptin levels would be positively correlated with fatigue levels, as observed in patient cohorts of other disease states. 6, 8, 9 The difference in direction observed for the effect of leptin on fatigue suggests that the experience of CRF may be different from fatigue-associated processes in other disease states. The positive correlations between fatigue and adipokines had been mostly observed in patients with other conditions marked by inflammation. 6, 9, 10 For instance, in a cohort of patients with cardiovascular risk factors, plasma leptin levels were significantly and positively associated with fatigue score (r = 0.22, P < 0.001) and retained an independent association in a multiple logistic regression. 8 Yet in
another study evaluating patients with systemic lupus erythematosus, there was no significant association between adipokines and fatigue levels, but their correlation was reported to be negative. In that model, after adjustment for age, sex, race/ethnicity and BMI, leptin was negatively correlated with fatigue levels, measured using the Fatigue Severity Scale (β = −0.12, P = 0.61) and patient-reported fatigue scores (β = −0.066, P = 0.96). The correlations between adipokines and both physical activity and disease activity were explained by differences in BMI. 32 These observed differences in CRF may also be nuanced and subjected to changes that depend on the individual sub-domains of CRF being examined. While CRF is a multidimensional construct, it is possible that not all facets of fatigue are equally associated with changes in adipokine levels. This is supported by our results in which plasma leptin levels were significantly correlated with the sub-domains of general, emotional and mental fatigue but not the physical and vigour sub-domains. In the final model, leptin was significantly correlated with only the total MFSI-SF scores but not the remaining sub-domains. This reinforces the need for studies to study the specific domains of fatigue more closely.
With regard to individual subdomains of fatigue, anxiety and depression continued to be strong predictors of fatigue levels over time, showing significant correlations with all five sub-domains. This observation was also reported in a separate cohort of breast cancer survivors, in which the research team reported that patients diagnosed with depression and anxiety before chemotherapy were at higher risk of fatigue onset at a later period. 3 This finding suggests that some psychological symptoms may form a fairly stable symptom cluster with CRF. It also supports the possibility that anxiety and depression add to the stress response and weaken the immune system, triggering inflammatory mediators involved in CRF and leading to pro-inflammatory changes in the body. 33 These findings are aligned with reviews reporting depression and anxiety as prominent correlates of CRF, 25, 33, 34 and lend strength to the argument that psychological distress needs to be accounted for when investigating the usefulness of leptin as a biomarker for CRF.
Based on our findings, it would be interesting to explore the relationships between leptin and other pro-inflammatory biomarkers.
Various cytokines such as TNF-α, IL-6 and IL-1 can induce metabolic changes by mimicking the action of neuropeptides such as leptin because of their structural similarity. 35 A decrease in food intake would usually suppress leptin expression, but in the presence of some cytokines, plasma leptin levels can be increased and work against the normal compensatory mechanisms set in place for leptin levels to regulate appetite. A possible explanation for the decrease in leptin levels with higher fatigue levels could be that an adaptive reduction of energy expenditure has been induced, resulting in increased appetite in response to metabolic impairment induced by cancer-related inflammation. It might also be more meaningful to evaluate the ratio of plasma leptin to other known pro-inflammatory cytokines to interpret inflammatory status, especially if they work as a network and if their levels affect each other. In the pathogenesis of some autoimmune diseases, leptin has been characterised together with adiponectin and resistin. 32, 36 In an ovarian cancer study, pro-inflammatory cytokines such as IL-6 and TNF-α were reported to induce an acute-phase protein response that contributed to altered energy TA B L E 5 Association of plasma leptin levels against total MFSI-SF score after adjusting for statistically significant covariates metabolism, which regulated leptin levels. 29 In another cohort of lung cancer patients, 37 the research team found significant positive associations among plasma levels of TNF-α, IL-1 and CRF. Together, these studies and our results suggest that leptin should be included in studies in which relationships between fatigue and cytokines are explored.
One strength of this study was the use of a longitudinal study design with repeated measurements of outcomes at various time points, which allowed us to determine whether a decrease in leptin levels signalled a rise in the fatigue experienced by breast cancer patients at a separate time point. Most of the current fatigue studies have been cross-sectional so far, 8, 9 and are not able to track the trajectories between fatigue and other variables, In conclusion, our data show that there is an inverse correlation between plasma leptin levels and fatigue levels over time in early-stage breast cancer patients undergoing chemotherapy. The association with total score remained statistically significant after adjusting for known confounders of CRF, enabling leptin to function as a biomarker that could predict onset of CRF.
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